Home
    • Plans Blog Contact
    ADC Therapeutics SA logo

    ADC Therapeutics SA

    ADCT
    Last price US$1.01
    Market cap US$164.0m
    12M price change -68.34%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Halozyme Therapeutics IncHALO Industry peer Corcept Therapeutics IncorporatedCORT Industry peer Exelixis IncEXEL Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    ADC Therapeutics SA Overview

    Industry: Biotechnology

    Sector: Healthcare

    Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for ADC Therapeutics SA into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Aug 13, 2026

    Quarterly result summary

    Revenue was $18.6M (reported). Net loss was -$16.6M. Cash was $219.1M.

    Revenue $18.6M reported
    Net loss -$16.6M reported
    Cash $219.1M reported

    What changed

    • Revenue reported to $18.6M.

    Guidance / outlook

    The Company anticipates growth starting in 2027. Recently, the Company held a pre-supplemental Biologics License Application (sBLA) meeting with the U.

    Earnings material Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q Aug 13, 2026 SEC filing FORM 8-K Aug 13, 2026 SEC filing 10-Q May 04, 2026 SEC filing 8-K May 04, 2026 Earnings release Earnings release May 04, 2026 SEC filing 10-K Mar 10, 2026 SEC filing 8-K Mar 10, 2026 Earnings release Earnings release Mar 10, 2026 SEC filing 8-K Jan 08, 2026 Earnings release Earnings release Jan 08, 2026 SEC filing 10-Q Nov 10, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 2.00/5
    ADC Therapeutics SA earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Return on Equity

    Score 2.84/5
    ADC Therapeutics SA stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    ADC Therapeu... ADCT US$164.0m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 1.26/5
    ADC Therapeutics SA olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    ADC Therapeu... ADCT US$164.0m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Leverage

    Score 1.59/5
    ADC Therapeutics SA registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    ADC Therapeu... ADCT US$164.0m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Reported currency
    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    ADC Therapeutics SA logo

    ADC Therapeutics SA

    US$1.01

    US$164.0m

    -10.62%

    -68.34%